Trivalent anti-TRAIL-R1 nano-agonist molecule1Alternative Names: TTR nano-agonist molecule1; TTR1 agonist; TTR1 nano-agonist
Latest Information Update: 08 Feb 2017
At a glance
- Originator Teikyo University
- Developer SymBio Pharmaceuticals; Teikyo University
- Class Antibodies
- Mechanism of Action TRAIL receptor 1 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer